多发性骨髓瘤患者SARS-CoV-2疫苗免疫原性:系统综述与Meta分析
该系统综述与Meta分析纳入15项研究(其中5项进入Meta分析),评估多发性骨髓瘤(MM)患者接种COVID-19疫苗的免疫原性及影响因素。接种2剂mRNA疫苗后抗刺突抗体应答率平均为78.2%(范围55.8%-94.2%),功能性T淋巴细胞阳性应答率平均为44.2%(范围34.2%-48.5%)。高危细胞遗传学或接受抗CD38治疗者体液免疫应答可能性较低,未接受活跃MM治疗者应答可能性较高。
要点
- MM患者接种2剂mRNA COVID-19疫苗后抗刺突抗体应答率平均78.2%(范围55.8%-94.2%)。
- 高危细胞遗传学患者体液免疫应答的合并OR为0.36(95%CI 0.18-0.69),I²=0%。
- 未接受活跃MM治疗者应答的合并OR为2.42(95%CI 1.10-5.33),I²=7%。
核心结论
- MM患者对mRNA COVID-19疫苗的体液和细胞免疫应答率较低。
- 需进一步研究确定最佳疫苗剂量并评估单克隆抗体用于暴露前预防。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、ISI Web of Science、Cochrane图书馆和Clinicaltrials.gov,检索时间从建库至2022年5月24日(PROSPERO: CRD42021277005)。
- 共纳入15项研究进入系统综述,其中5项纳入Meta分析。
主要发现
- 接种2剂mRNA COVID-19疫苗后功能性T淋巴细胞阳性应答率平均为44.2%(范围34.2%-48.5%)。
- 接种1剂和2剂mRNA COVID-19疫苗后抗刺突抗体应答率平均分别为42.7%(范围20.8%-88.5%)和78.2%(范围55.8%-94.2%)。
- 接种1剂和2剂mRNA COVID-19疫苗后中和抗体应答率平均分别为25%(1项研究)和62.7%(范围53.3%-68.6%)。
- 高危细胞遗传学患者体液免疫应答的合并OR为0.36(95%CI 0.18-0.69),I²=0%。
- 接受抗CD38治疗患者体液免疫应答的合并OR为0.42(95%CI 0.22-0.79),I²=14%;未接受活跃MM治疗者应答的合并OR为2.42(95%CI 1.10-5.33),I²=7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究确定最佳疫苗剂量并评估单克隆抗体用于暴露前预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral immune response in patients with MM. Two reviewers independently conducted a literature search in MEDLINE, Embase, ISI Web of Science, Cochrane library, and Clinicaltrials.gov from existence until 24 May 24 2022. (PROSPERO: CRD42021277005). A total of 15 studies were included in the systematic review and 5 were included in the meta-analysis. The average rate (range) of positive functional T-lymphocyte response was 44.2% (34.2%-48.5%) after 2 doses of messenger RNA (mRNA) COVID-19 vaccines. The average antispike antibody response rates (range) were 42.7% (20.8%-88.5%) and 78.2% (55.8%-94.2%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. The average neutralizing antibody response rates (range) were 25% (1 study) and 62.7% (53.3%-68.6%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. Patients with high-risk cytogenetics or receiving anti-CD38 therapy were less likely to have a humoral immune response with pooled odds ratios of 0.36 (95% confidence interval [95% CI], 0.18, 0.69), I2 = 0% and 0.42 (95% CI, 0.22, 0.79), I2 = 14%, respectively. Patients who were not on active MM treatment were more likely to respond with pooled odds ratio of 2.42 (95% CI, 1.10, 5.33), I2 = 7%. Patients with MM had low rates of humoral and cellular immune responses to the mRNA COVID-19 vaccines. Further studies are needed to determine the optimal doses of vaccines and evaluate the use of monoclonal antibodies for pre-exposure prophylaxis in this population.
引用
- Chuleerarux N, Manothummetha K, Moonla C, et al. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022. PMID: 36538342. doi:10.1182/bloodadvances.2022008530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。